bioRxiv (Cold Spring Harbor Laboratory),
Год журнала:
2023,
Номер
unknown
Опубликована: Дек. 28, 2023
ABSTRACT
Background
Sex,
as
a
critical
biological
variable,
has
historically
been
underappreciated,
despite
the
pervasive
influence
of
sexual
dimorphism
across
physiological
and
pathological
processes.
A
significant
obstacle
to
advancing
sex-biased
research
is
absence
an
effective
animal
model.
In
recent
years,
castration
emerged
potential
model
for
elucidating
sex-based
differences
in
context
healthy
aging,
where
it
shown
equalize
lifespan
growth
trajectories
genetically
diverse
mice.
However,
molecular
shifts
induced
by
common
laboratory
models,
such
C57BL/6
mice,
broader
applicability
this
other
sex-related
contexts
remain
largely
unexplored.
Methods
We
employed
multi-omics
observational
analyses
investigate
changes
associated
with
sex
hormones
following
castration.
analyzed
serum,
kidney,
liver
samples
from
12-week-old
18-month-old
castrated
male
alongside
intact
female
counterparts.
The
was
further
applied
assess
cisplatin-induced
toxicity
age-related
cognitive
decline
comparison
unaltered
controls.
Results
LC-MS/MS
metabolomics
revealed
that
males
exhibited
substantial
alterations
steroid
hormone
levels
increased
concentrations
antioxidant
compounds,
taurine,
identical
diets.
Integrated
metabolome-transcriptome
analysis
confirmed
distinct
patterns
lipid
peroxidation
oxidative
stress
sham-operated
female,
male,
Histopathological
evaluations
cisplatin
treatment
aging-related
behavioral
tests
demonstrated
model’s
utility
investigating
sex-dependent
drug
decline.
These
findings
underscored
role
modulating
both
defense
mechanisms
performance.
Conclusion
This
study
provides
systematic
spectrum
on
demonstrates
its
capacity
feminize
metabolic
transcriptomic
profiles,
establishing
valuable
tool
exploring
hormone-driven
differences.
Our
lay
groundwork
mechanistic
studies
broaden
applications
biomedical
domains.
Cancers,
Год журнала:
2025,
Номер
17(5), С. 732 - 732
Опубликована: Фев. 21, 2025
In
the
era
of
precision
medicine,
mounting
evidence
suggests
that
time
therapy
administration,
or
chronotherapy,
has
a
great
impact
on
treatment
outcomes.
Chronotherapy
involves
planning
timing
by
considering
circadian
rhythms,
which
are
24
h
oscillations
in
behavior
and
physiology
driven
synchronized
molecular
clocks
throughout
body.
The
value
chronotherapy
cancer
is
currently
under
investigation,
notably
effects
efficacy
side
effects.
Immune
checkpoint
inhibitor
(ICI)
promising
treatment.
However,
many
patients
still
experience
disease
progression
need
to
stop
early
due
There
accumulating
day
at
ICI
administered
can
have
substantial
effect
efficacy.
Thus,
it
important
investigate
intersections
this
review,
we
provide
brief
overview
rhythms
context
immunity
cancer.
Additionally,
outline
current
applications
for
We
synthesize
29
studies
conducted
date
examine
time-of-day
administration
therapy,
its
associated
effects,
sex
differences
both
also
discuss
potential
mechanisms
underlying
these
observed
results.
Finally,
highlight
challenges
area
future
directions
research,
including
chronotherapeutic
personalized
medicine
approach
tailors
individual
patients’
rhythms.
Cells,
Год журнала:
2025,
Номер
14(4), С. 273 - 273
Опубликована: Фев. 13, 2025
Autophagy,
a
cellular
process
essential
for
maintaining
homeostasis,
plays
fundamental
role
in
recycling
damaged
components
and
adapting
to
stress.
The
dysregulation
of
autophagy
is
implicated
numerous
human
diseases,
including
cancer,
where
it
exhibits
dual
as
both
suppressor
promoter,
depending
on
the
context
stage
tumor
development.
significant
sex
differences
observed
autophagic
processes
are
determined
by
biological
factors,
such
genetic
makeup
hormones.
Estrogens,
through
their
interaction
with
specific
receptors,
modulate
influence
progression,
therapy
resistance,
immune
response
tumors.
In
females,
escape
from
X
inactivation
estrogen
signaling
may
be
responsible
advantages,
terms
lower
incidence
longer
survival,
oncology.
Women
often
show
better
responses
traditional
chemotherapy,
while
men
respond
immunotherapy.
action
hormones
system
could
contribute
these
differences.
However,
women
experience
more
severe
adverse
reactions
anticancer
drugs.
estrogen/autophagy
crosstalk-involved
multiple
aspects
tumor,
i.e.,
development,
progression
therapy-deserves
an
in-depth
study,
highlight
sex-specific
mechanisms
useful
designing
innovative
gender-tailored
treatments
perspective
precision
medicine.
British Journal of Haematology,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 23, 2025
Summary
There
are
clear
sex‐based
differences
in
the
incidence,
risk
factors
and
mortality
of
most
haematologic
malignancies
(HM).
Despite
known
physiology,
haematopoiesis,
molecular
profiles,
drug
pharmacokinetics,
treatment‐related
toxicities
treatment
experience,
males
females
receive
standardized
identical
for
HMs.
Previous
published
work
has
demonstrated
disparities
female
representation
cancer
clinical
trials
highlighted
a
paucity
information
on
differential
outcomes
by
sex.
We
analysed
references
182
which
form
basis
recent
guidelines
from
National
Comprehensive
Cancer
Network
found
minority
(17/9.3%)
did
not
report
sex
distribution
trial
participants.
However,
majority
(165/90.6%)
sex‐disaggregated
outcomes.
Of
those
that
did,
36.5%
showed
outcome
Academic
leadership
women
assessed
as
well
committees
was
disproportionately
lower
than
their
profession.
call
all
leaders,
consortia
guideline
builders
to
include
data
analyses,
reporting
these
transparent
manner
(as
per
regulations
mandating
such
reporting),
investigators
assess
whether
aetiological
differ
These
actions
will
enhance
personalized
prevention,
therapy
follow‐up.
Nature Communications,
Год журнала:
2024,
Номер
15(1)
Опубликована: Апрель 9, 2024
Many
aspects
of
human
health
and
disease
are
influenced
by
sex
as
a
biological
variable
gender
social
construct.
A
recent
study
from
Nature
Communications
reported
the
landscape
outcome
comparisions
in
oncology
clinical
trials,
highlighting
need
for
more
thorough
reporting
differences.
Nucleic Acids Research,
Год журнала:
2024,
Номер
53(D1), С. D1443 - D1459
Опубликована: Ноя. 13, 2024
The
NIH
policy
on
sex
as
biological
variable
(SABV)
emphasized
the
importance
of
sex-based
differences
in
precision
oncology.
Over
50%
clinically
actionable
oncology
genes
are
sex-biased,
indicating
drug
efficacy.
Research
has
identified
non-reproductive
cancers,
highlighting
need
for
comprehensive
cancer
data.
We
therefore
developed
OncoSexome,
a
multidimensional
knowledge
base
describing
(https://idrblab.org/OncoSexome/)
across
four
key
topics:
antineoplastic
drugs
and
responses
(SDR),
oncology-related
biomarkers
(SBM),
risk
factors
(SRF)
microbial
landscape
(SML).
SDR
covers
2051
anticancer
drugs;
SBM
describes
12
551
sex-differential
biomarkers;
SRF
illustrates
350
sex-dependent
factors;
SML
demonstrates
1386
microbes
with
abundances
associated
development.
OncoSexome
is
unique
illuminating
multifaceted
influences
cancer,
providing
both
external
endogenous
contributors
to
development
broadest
oncological
classes.
Given
increasing
global
research
interest
differences,
expected
impact
future
practices
significantly.
